-
公开(公告)号：US12121572B2
公开(公告)日：2024-10-22
申请号：US17502185
申请日：2021-10-15
发明人： Toni Weinschenk , Andrea Mahr , Jens Fritsche , Phillip Mueller , Anita Wiebe , Sarah Kutscher
IPC分类号： A61K39/00 , A61K35/17 , A61K38/04 , C07K7/00 , C07K7/06 , C07K14/435 , C07K14/725 , C07K14/74 , C07K16/18 , C12N5/0783 , C12N15/115 , A61K35/12 , A61K51/10 , C07K7/08 , G01N33/68
CPC分类号： A61K39/0011 , A61K35/17 , A61K38/04 , C07K7/00 , C07K7/06 , C07K14/435 , C07K14/7051 , C07K14/70539 , C07K16/18 , C12N5/0636 , C12N15/115 , A61K2035/124 , A61K39/00111 , A61K2039/5154 , A61K2039/5158 , A61K51/1057 , C07K7/08 , C07K2317/70 , C07K2319/40 , C12N2310/16 , C12N2501/998 , G01N33/6803
摘要： A peptide consists of the amino acid sequence GLIHLEGDTV (SEQ ID NO: 53) in the form of a pharmaceutically acceptable salt, in which the peptide has the ability to bind to an MHC class-I molecule and, when bound to MHC, is capable of being recognized by CD8 T cells. A composition contains a peptide consisting of the amino acid sequence GLIHLEGDTV (SEQ ID NO: 53), an adjuvant, and a pharmaceutically acceptable carrier.
-
公开(公告)号：US12116423B2
公开(公告)日：2024-10-15
申请号：US17461115
申请日：2021-08-30
发明人： Meredith Hay , John Konhilas , Robin L. Polt , Evan Jones , Lajos Szabo
摘要： The present invention provides oligopeptides, in particular, Ang-(1-7) derivatives, and methods for using and producing the same. In one particular embodiment, oligopeptides of the invention have higher blood-brain barrier penetration and/or in vivo half-life compared to the native Ang-(1-7), thereby allowing oligopeptides of the invention to be used in a wide variety of clinical applications including in treatment of cognitive dysfunction and/of impairment.
-
公开(公告)号：US12097248B2
公开(公告)日：2024-09-24
申请号：US17508230
申请日：2021-10-22
发明人： Toni Weinschenk , Andrea Mahr , Jens Fritsche , Phillip Mueller , Anita Wiebe , Sarah Kutscher
IPC分类号： A61K39/00 , A61K35/17 , A61K38/04 , C07K7/00 , C07K7/06 , C07K14/435 , C07K14/725 , C07K14/74 , C07K16/18 , C12N5/0783 , C12N15/115 , A61K35/12 , A61K51/10 , C07K7/08 , G01N33/68
CPC分类号： A61K39/0011 , A61K35/17 , A61K38/04 , C07K7/00 , C07K7/06 , C07K14/435 , C07K14/7051 , C07K14/70539 , C07K16/18 , C12N5/0636 , C12N15/115 , A61K2035/124 , A61K39/00111 , A61K2039/5154 , A61K2039/5158 , A61K51/1057 , C07K7/08 , C07K2317/70 , C07K2319/40 , C12N2310/16 , C12N2501/998 , G01N33/6803
摘要： A peptide consists of the amino acid sequence GVLPGLVGV (SEQ ID NO: 56) in the form of a pharmaceutically acceptable salt, in which the peptide has the ability to bind to an MHC class-I molecule and, when bound to MHC, is capable of being recognized by CD8 T cells. A composition contains a peptide consisting of the amino acid sequence GVLPGLVGV (SEQ ID NO: 56), an adjuvant, and a pharmaceutically acceptable carrier.
-
公开(公告)号：US12090189B2
公开(公告)日：2024-09-17
申请号：US18474456
申请日：2023-09-26
发明人： Daiqing Liao , Iqbal Mahmud , Guimei Tian
摘要： Disclosed herein is a method for treating cancer in a subject that involves administering to the subject a therapeutically effective amount of a composition comprising a polypeptide that comprises an amino acid sequence corresponding to at the C-terminal SUMO-interacting motif (SIM2) of a DAXX protein. The disclosed polypeptide is not a functional DAXX protein but competes with endogenous DAXX for binding to SUMO.
-
公开(公告)号：US12011475B2
公开(公告)日：2024-06-18
申请号：US16490543
申请日：2018-02-28
发明人： De Wei , Yi Ding , Xiaomei Li , Wen Yu , Xiaohong Chen , Ling Xiao , Rui Chen , Ling Chen
摘要： Disclosed in the present invention are a polypeptide fragment, a derivative of the polypeptide fragment, and applications of the derivative of the polypeptide in the preparation of drugs for preventing and treating fibrosis diseases.
-
公开(公告)号：US11975040B2
公开(公告)日：2024-05-07
申请号：US16309957
申请日：2017-06-16
IPC分类号： A61K38/02 , A61K9/00 , A61K38/04 , A61P9/00 , A61P19/00 , A61P19/08 , A61P25/28 , A61P35/00 , A61P43/00 , C07K7/50
CPC分类号： A61K38/02 , A61K9/0019 , A61K9/0053 , A61K38/04 , A61P19/00 , A61P19/08 , A61P25/28 , A61P35/00 , A61P43/00 , C07K7/50
摘要： The present invention provides a Plexin-binding regulating agent containing a cyclic peptide having an Arg-Trp-Thr structure or a Leu-Ser-Trp structure or a pharmaceutically acceptable salt of the cyclic peptide.
-
7.发明公开公开(公告)号：US20240122987A1
公开(公告)日：2024-04-18
申请号：US18379740
申请日：2023-10-13
发明人： Andrew P. CAP , James A. BYNUM , Xiaowu WU
IPC分类号： A61K35/19 , A61K9/00 , A61K31/137 , A61K31/437 , A61K31/4418 , A61K31/472 , A61K31/506 , A61K31/513 , A61K31/5377 , A61K35/14 , A61K35/16 , A61K35/18 , A61K38/04 , A61K38/095 , A61K38/36 , A61K38/38 , A61K47/26 , A61P7/04
CPC分类号： A61K35/19 , A61K9/0019 , A61K31/137 , A61K31/437 , A61K31/4418 , A61K31/472 , A61K31/506 , A61K31/513 , A61K31/5377 , A61K35/14 , A61K35/16 , A61K35/18 , A61K38/043 , A61K38/095 , A61K38/363 , A61K38/38 , A61K47/26 , A61P7/04
摘要： A majority of military casualties occur during the pre-hospital period. The cause of death is largely associated with massive traumatic bleeding that leads to organ damage due to sustained hypoxia. Currently, therapeutics are lacking at the point of injury to mitigate hypoxic damage and maintain the survivability of severe hemorrhage prior to reaching medical facilities. This invention addresses that by introducing a method of co-administering prolyl hydroxylase domain inhibitor (PHDi, MK-8617), anti-fibrinolytic agent (tranexamic acid), and bradykinin receptor antagonist (icatibant) as anti-hemorrhage agents in combination with resuscitation fluid treatment with colloid solution of 25% human albumin that has an advantage of relatively small volume requirement to maintain blood volume. In addition, a kit comprising anti-hemorrhage agents that can be easily carried to the battlefield is also provided here. The therapeutic application of those agents on or near the point of injury can stabilize hypoxia inducible factor-1 alpha and enhance blood clot formation, which improves the patient's cellular adaptation to hypoxia and reduce hemorrhage, and thus can decrease organ failure and increase the patient's survivability.
-
公开(公告)号：US11807674B2
公开(公告)日：2023-11-07
申请号：US17099308
申请日：2020-11-16
发明人： Mark Leslie Smythe , Gregory Thomas Bourne , Simone Vink , Brian Troy Frederick , Praveen Madala , Anne Pernille Tofteng Shelton , Jacob Ulrik Fog
IPC分类号： A61K38/10 , A61K38/08 , A61K38/04 , C07K5/00 , C07K7/00 , C07K16/00 , C07K17/00 , C07K14/575 , A61K38/00
CPC分类号： C07K14/575 , A61K38/00
摘要： The present invention relates, inter alia, to certain hepcidin peptide analogues, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.
-
公开(公告)号：US20230330238A1
公开(公告)日：2023-10-19
申请号：US18030433
申请日：2021-10-14
发明人： Henry D. Herce , Loren D. Walensky
IPC分类号： A61K47/55 , A61K31/454 , A61K31/427 , A61K38/04 , A61K31/4166 , A61P31/14
CPC分类号： A61K47/55 , A61K31/4166 , A61K31/427 , A61K31/454 , A61K38/04 , A61P31/14
摘要： The present application describes chimeras which target and degrade essential viral proteins or host proteins involved in viral pathogenesis. In particular, the chimeras of this application combine a moiety that binds to a target protein (such as a coronaviral papain-like protease (PLpro), main protease (Mpro), or other non-structural proteins (e.g., NSP9 or NSP12); or a host protein, such as bromodomain 2, bromodomain 3, or bromodomain 4)), with a moiety that recruits a protein degrader, thereby degrading the target protein. In some instances, the chimera simultaneously induces p53, which itself has anti-viral activity, by engaging HDM2 as the protein degrader. The disclosure also relates to methods of using such chimeras in the prevention and treatment of viral infections, particularly viral infections (such as COVID-19) caused by coronaviruses (such as SARS-CoV-2).
-
公开(公告)号：US11786583B2
公开(公告)日：2023-10-17
申请号：US17245918
申请日：2021-04-30
发明人： Toni Weinschenk , Andrea Mahr , Jens Fritsche , Phillip Mueller , Anita Wiebe , Sarah Kutscher
IPC分类号： A61K39/00 , A61K38/04 , C07K7/06 , C07K7/00 , A61K35/17 , C07K16/18 , G01N33/68 , C07K14/435 , C07K7/08 , A61K51/10 , A61K35/12 , C12N5/0783 , C12N15/115 , C07K14/725 , C07K14/74
CPC分类号： A61K39/0011 , A61K35/17 , A61K38/04 , C07K7/00 , C07K7/06 , C07K14/435 , C07K16/18 , G01N33/6803 , A61K39/00111 , A61K51/1057 , A61K2035/124 , A61K2039/5154 , A61K2039/5158 , C07K7/08 , C07K14/7051 , C07K14/70539 , C07K2317/70 , C07K2319/40 , C12N5/0636 , C12N15/115 , C12N2310/16 , C12N2501/998
摘要： A peptide consists of the amino acid sequence KLSPTVVGL (SEQ ID NO: 6) in the form of a pharmaceutically acceptable salt, in which the peptide has the ability to bind to an MHC class-I molecule and, when bound to MHC, is capable of being recognized by CD8 T cells. A composition contains a peptide consisting of the amino acid sequence KLSPTVVGL (SEQ ID NO: 6), an adjuvant, and a pharmaceutically acceptable carrier.
-
-
-
-
-
-
-
-
-
搜索结果
2916 条记录 (耗时 0.041 秒)
